Cover Image
市場調查報告書

Celentyx Ltd. 的產品平台分析

Celentyx Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226206
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
Celentyx Ltd. 的產品平台分析 Celentyx Ltd. - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 21 Pages
簡介

Celentyx Ltd. 是英國的生物科技企業,提供為早期分析人體免疫細胞上的藥劑作用所用的免疫評估平台。

本報告提供Celentyx Ltd. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Celentyx Ltd. 的基本資料

  • Celentyx Ltd. 概要
  • 主要資訊
  • 企業資料

Celentyx Ltd. :R&D概要

  • 主要的治療範圍

Celentyx Ltd. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Celentyx Ltd. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

Celentyx Ltd. :藥物簡介

  • CX-1001
  • CX-1010
  • CX-1020
  • CX-1030
  • CX-1040

Celentyx Ltd. :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Celentyx Ltd. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06974CDB

Summary

Global Markets Direct's, 'Celentyx Ltd. - Product Pipeline Review - 2015', provides an overview of the Celentyx Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celentyx Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celentyx Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celentyx Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celentyx Ltd.'s pipeline products

Reasons to buy

  • Evaluate Celentyx Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celentyx Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celentyx Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celentyx Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celentyx Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celentyx Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celentyx Ltd. Snapshot
    • Celentyx Ltd. Overview
    • Key Information
    • Key Facts
  • Celentyx Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Celentyx Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Celentyx Ltd. - Pipeline Products Glance
    • Celentyx Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Celentyx Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Celentyx Ltd. - Drug Profiles
    • CX-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1030
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1040
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celentyx Ltd. - Pipeline Analysis
  • Celentyx Ltd. - Pipeline Products by Target
  • Celentyx Ltd. - Pipeline Products by Molecule Type
  • Celentyx Ltd. - Pipeline Products by Mechanism of Action
  • Celentyx Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celentyx Ltd., Key Information
  • Celentyx Ltd., Key Facts
  • Celentyx Ltd. - Pipeline by Indication, 2015
  • Celentyx Ltd. - Pipeline by Stage of Development, 2015
  • Celentyx Ltd. - Monotherapy Products in Pipeline, 2015
  • Celentyx Ltd. - Phase I, 2015
  • Celentyx Ltd. - Discovery, 2015
  • Celentyx Ltd. - Pipeline by Target, 2015
  • Celentyx Ltd. - Pipeline by Molecule Type, 2015
  • Celentyx Ltd. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Celentyx Ltd. - Pipeline by Top 10 Indication, 2015
  • Celentyx Ltd. - Pipeline by Stage of Development, 2015
  • Celentyx Ltd. - Monotherapy Products in Pipeline, 2015
Back to Top